Judith Ann Clements

Judith Ann Clements

Auto-generated profile, based on publicly available information

Judith Ann Clements

Queensland University of Technology

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2007 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
HHHonor Hugo
Honor Hugo
MAM Leigh Ackland
M Leigh Ackland
TBTony Blick
Tony Blick
MLMitchell Lawrence
Mitchell Lawrence
JCJudith A. Clements
Judith A. Clements
ETErik Walter Thompson
Erik Walter Thompson
Like a set of bookends, cellular, molecular, and genetic changes of the beginnings of life mirror those of one of the most common cause of death—metastatic cancer. Epithelial to mesenchymal transition (EMT) is an important change in cell phenotype which allows the escape of epithelial cells from the structural constraints imposed by tissue architecture, and was first recognized by Elizabeth Hay in the early to mid 1980's to be a central process in early embryonic morphogenesis. Reversals of these changes, termed mesenchymal to epithelial transitions (METs), also occur and are important in tissue construction in normal development. Over the last decade, evidence has mounted for EMT as the means through which solid tissue epithelial cancers invade and metastasize. However, demonstrating this potentially rapid and transient process in vivo has proven difficult and data connecting the relevance of this process to tumor progression is still somewhat limited and controversial. Evidence for an important role of MET in the development of clinically overt metastases is starting to accumulate, and model systems have been developed. This review details recent advances in the knowledge of EMT as it occurs in breast development and carcinoma and prostate cancer progression, and highlights the role that MET plays in cancer metastasis. Finally, perspectives from a clinical and translational viewpoint are discussed. J. Cell. Physiol. 213: 374–383, 2007.

1 November 2010 in Biomaterials
Verified
Journal Article
Closed access
Daniela LoessnerDaniela Loessner
Daniela Loessner
KSKathryn S. Stok
Kathryn S. Stok
MLMatthias P. Lutolf
Matthias P. Lutolf
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
JCJudith A. Clements
Judith A. Clements
SRSimone C. Rizzi
Simone C. Rizzi

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TIThe COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
The COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
RERosalind Eeles
Rosalind Eeles
TBThe Australian Prostate Cancer Bioresource
The Australian Prostate Cancer Bioresource
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
TCThe UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
The UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
DEDouglas F Easton
Douglas F Easton

14 September 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AOAli Amin Al Olama
Ali Amin Al Olama
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
SBSonja I Berndt
Sonja I Berndt
DCDavid V Conti
David V Conti
FSFredrick Schumacher
Fredrick Schumacher
CHChristopher A Haiman
Christopher A Haiman
Rosalind Eeles, Christopher Haiman and colleagues report genome-wide association and meta-analyses of prostate cancer in populations of European, African, Japanese and Latino ancestry. They identify 23 new susceptibility loci, including one associated with early-onset prostate cancer. Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of >10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10−8; 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.

20 September 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
RERosalind Eeles
Rosalind Eeles
TCThe UK ProtecT Study Collaborators
The UK ProtecT Study Collaborators
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
DEDouglas F Easton
Douglas F Easton

1 January 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JHJohn D. Hooper
John D. Hooper
JCJudith A. Clements
Judith A. Clements
JQJames P. Quigley
James P. Quigley
TAToni M. Antalis
Toni M. Antalis
Cell surface proteolysis has emerged as an important mechanism for the generation of biologically active proteins that mediate a diverse range of cellular functions. The proteolytic activities of membrane anchored proteins, such as a disintegrin-like and metalloproteinase containing proteins (ADAMs) and membrane-type matrix metalloproteinases (MT-MMPs), are thought to play central roles in these cell surface activating events